Inaxaplin
A medication used for the treatment of APOL1-mediated kidney disease
Inaxaplin is a medication used in the treatment of APOL1-mediated kidney disease. It is a small molecule inhibitor that targets the effects of certain genetic variants in the APOL1 gene, which are associated with an increased risk of kidney disease in individuals of African descent.
Mechanism of Action[edit | edit source]
Inaxaplin works by inhibiting the activity of the APOL1 protein variants that are implicated in kidney damage. These variants, known as G1 and G2, are associated with increased risk of chronic kidney disease (CKD) and end-stage renal disease (ESRD). The drug aims to reduce the toxic effects of these variants on kidney cells, thereby slowing the progression of kidney disease.
Clinical Use[edit | edit source]
Inaxaplin is specifically indicated for patients with APOL1-mediated kidney disease, a condition that is more prevalent in individuals of African ancestry due to the higher frequency of APOL1 risk variants in this population. The medication is part of a targeted therapy approach, aiming to address the underlying genetic cause of the disease rather than just managing symptoms.
Development and Approval[edit | edit source]
Inaxaplin was developed following research that identified the role of APOL1 variants in kidney disease. Clinical trials demonstrated its efficacy in reducing proteinuria and slowing the decline in kidney function in patients with these genetic variants. The drug received regulatory approval after showing significant benefits in these trials.
Side Effects[edit | edit source]
Common side effects of Inaxaplin include headache, nausea, and fatigue. More serious adverse effects are rare but can include liver enzyme elevations and hypersensitivity reactions. Patients are monitored regularly to manage any potential side effects.
Research and Future Directions[edit | edit source]
Ongoing research is focused on further understanding the role of APOL1 in kidney disease and exploring additional therapeutic strategies. Inaxaplin represents a significant advancement in personalized medicine, offering a treatment option tailored to the genetic profile of patients.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
